Evogene (EVGN) Q3 2026 earnings review
Evogene's drug research advances, but new shares fund its spending
Evogene, which designs drug and crop molecules with AI, paid for its research by selling new shares. Revenue shrank by more than half after a Bayer weed-killer project ended. The group used $2.4 million of cash, and share sales covered almost all of it. Chief executive Ofer Haviv focused on early lab results from two programs Evogene owns.
| Revenue | $141,000 $312,000 a year ago (−55%) |
|---|---|
| Cash used in the quarter | $2.4 million $2.1 million last quarter; about $1.9 million without a one-off insurance payment |
| Shares outstanding | 18.1 million 8.7 million at the end of 2025 |
| Full-year cash-use plan | Not repeated $8.5–9.5 million set last quarter; leaves about $1.7 million for Q4 by our math |
⚖️ Verdict: 🔴 Bearish
The story got worse because Evogene now depends on new shares, and its share count has more than doubled since December. Spending also ran above its full-year plan's pace, though a one-off insurance bill explains the gap. The good news: Evogene keeps all rights to the programs behind Haviv's lab results.
The question now is whether ChemPass, its design software, wins a fee-paying partner before the cash runs short. Either such a deal arrives, or share sales keep shrinking each owner's stake. The full-year results will show whether a deal with stated fees has come.
🐂 Bull Case
Two In-House Programs Report Early Lab Results
Evogene uses ChemPass, its AI software for designing drug and crop-chemical molecules, on programs it owns outright. Chief executive Ofer Haviv said this work aims to build "proprietary assets fully owned and managed by Evogene".
In the drug program, which targets an immune reaction after stem-cell transplants, Haviv said the molecules worked "at nanomolar concentrations", meaning at tiny doses. AgPlenus, the crop unit, found compounds that act against strains of a wheat fungus that resist current sprays. On plant tissue, the best compounds cut disease by up to 75%, Haviv said.
Evogene keeps all the rights to owned programs, but it also pays the full cost, and every result so far comes from lab tests.
What to watch: whether the wheat-fungus compounds enter greenhouse trials by the fourth-quarter results. Haviv has said that is the stage when AgPlenus will approach the big chemical companies, so a start would make a paying partner possible.
Positives this quarter didn't test
Two positives from earlier quarters got no new numbers in the release or the slides, so this quarter did not test either of them.
- Partner collaborations for ChemPass, Evogene's AI design software: the count stood at six in the second quarter, and this release gives no new total.
- Google Cloud partnership: the second agreement, which adds AI agents to ChemPass, got no new milestone; a named result from it would move the case.
🐻 Bear Case
New Shares Paid for Nearly All the Spending
Evogene has almost no revenue, so cash decides how long its research runs. Last quarter, finance vice-president Polina Ravzin put 2026 cash use at $8.5–9.5 million. The case for the company rests on its cost cuts, which brought quarterly cash use down from $3.5 million a year earlier.
In the third quarter cash use rose again, and Evogene paid for almost all of it by selling new shares on the stock market.
- Cash used: $2.4 million, after $2.1 million in the second quarter
- Without a one-off directors' insurance payment: about $1.9 million, by our math
- Cash raised from new shares: $2.35 million
- Shares outstanding: 18.1 million, against 8.7 million in December
This matters because share sales, not savings, kept cash and deposits steady at $9.2 million. Each existing share now owns a far smaller slice of any future success. By our math, that cash lasts about four quarters at the current pace.
What to watch: fourth-quarter cash use, due with the full-year results. By our math, the 2026 plan leaves room for about $1.7 million, so a figure near that would show the cost cuts still hold.
Revenue Fell Again as the Bayer Project Ended
Haviv said Evogene aims to turn its technology into "differentiated, proprietary product candidates". None of its current partnerships has a disclosed fee, though, so revenue has little to build on.
Revenue fell to $141,000 from $312,000 a year earlier. The company blamed the "conclusion of the license and collaboration agreement with Bayer in May 2026", which ended a weed-killer project with its last large farm partner.
Deferred revenue, which is cash customers pay before Evogene does the work, slipped to $81,000 from $86,000 in June. No new paid work is building up behind the reported figure either.
What to watch: whether any partnership, old or new, comes with stated fees or milestone payments in the full-year results. Until one does, Evogene pays for all its research from its own cash.
Shareholder Disputes Added to Overhead Costs
Dissident investors challenged this year's annual meeting results. Evogene still lists a change in board control "due to the actions of dissident shareholders" as a risk.
General and administrative spending, or overhead, reached $1.11 million, up from $0.89 million in the second quarter. The company said about $0.3 million of it came from one-offs. It named "non-recurring legal expenses related to corporate governance" and a February deal with holders of rights to buy its shares.
This matters because Evogene funds research from a small cash pile, and legal bills compete for the same money. Without the one-offs, by our math, overhead would have fallen 26% from a year earlier.
What to watch: overhead in the fourth quarter, and whether Evogene names the cost of the dispute separately. A figure near this quarter's level without one-offs would show the savings are real.
Risks this quarter didn't answer
Five standing concerns got no clear answer in the release or in the slides that Evogene published for its results call.
- Investor outreach: Haviv promised meetings with investors after the summer, and the release reports none; the full-year results should show whether they happened.
- Warrant accounting: revaluing warrants, which are rights to buy shares, added only $163,000 of income, a quiet quarter after a $3.8 million charge earlier this year.
- Rivals in AI drug discovery: no new evidence either way; a partner paying fees would be the first test of whether Evogene can compete with larger platforms.
- Israel's security: Evogene still lists the aftermath of the region's wars as a risk, but it reported no disruption to its work.
- Former units: sold businesses added $483,000 of cash, and the release gave no update on ICL's next payment for Lavie Bio, the crop-microbe unit, or on Casterra, the castor-seed unit.
👓 Other Themes
Currency Moves Added to Research Costs
Evogene, based in Rehovot, Israel, reports its results in dollars. It said research spending rose partly because of "the impact of fluctuations in the USD/NIS exchange rate", the price of the dollar in Israeli shekels. The release did not give the size of that effect, so readers cannot yet separate currency from real cost growth.
💲 Other KPIs
Research spending turned up, rising 35% from a year ago after three quarters of declines. A year-ago grant and a grant-liability adjustment cut that period's costs by about $0.3 million. Without them, by our math, the increase was about 7%, so the underlying research budget is close to flat.
The part of the balance sheet that belongs to Evogene's own shareholders sank further below zero, from −$0.1 million in December. Losses outran the money from new shares. Total equity stays positive at $5.2 million only because outside owners hold $9.0 million of stakes in its subsidiaries.
Money customers owe Evogene dropped from $317,000 in December, yet it still exceeds a full quarter's revenue. In the third quarter the group also set aside $78,000 for debts it may not collect, its first such provision this year.
❓ Key Questions
Does the $8.5–9.5 million cash plan still hold?
The release did not repeat the full-year cash plan. By our math, meeting it requires fourth-quarter cash use of about $1.7 million, well below the third quarter's $2.4 million.
What fees do the ChemPass partners pay Evogene?
No partner deal has disclosed fees, milestones or royalties. After the Bayer project ended, revenue has no visible source, so Evogene must fund all research itself.
How many drug collaborations are active now?
Evogene counted six active drug collaborations in the second quarter. The release gives no new total, so readers cannot tell whether the partner list grew or stood still.
How many shares did Evogene sell, and at what price?
Share sales raised $2.35 million in the quarter. The number of shares and the average price would show how much each dollar raised cost existing owners.
What do the shareholder disputes cost, and when do they end?
Legal costs tied to governance helped lift overhead this quarter. A separate figure and a timeline would show how much research money the dispute takes.
